Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22940154 | 0.90 | CRBN (0.68) | CRBNDDB1CYP19A1 | |
| SCHEMBL24319166 | 0.86 | CRBN (0.60) | CRBNIKZF2DDB1CSNK1A1 | |
| SCHEMBL26107723 | 0.85 | CRBN (0.58) | CRBNIKZF2DDB1CSNK1A1 | |
| SCHEMBL31347063 | 0.85 | CRBN (0.58) | CRBNIKZF2DDB1CSNK1A1 | |
| SCHEMBL26518780 | 0.84 | CRBN (0.58) | CRBNCASP1CASP7HSD17B10IKZF2 | |
| SCHEMBL27097398 | 0.83 | CRBN (0.59) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL24745571 | 0.83 | CRBN (0.56) | CRBNIKZF2DDB1CSNK1A1 | |
| SCHEMBL30121132 | 0.82 | CRBN (0.63) | CRBNDDB1 | |
| SCHEMBL824532 | 0.82 | CRBN (0.63) | CRBNDDB1 | |
| SCHEMBL26075169 | 0.81 | CRBN (0.57) | CRBNCASP1CASP7IKZF2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303538-A1 | GALECTIN-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303538-A1 | GALECTIN-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-28 | — | — | US | disclosed |
| CN-115768768-A | Galectin-3 inhibitors | 百时美施贵宝公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2021242982-A1 | GALECTIN-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021180103-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021058017-A1 | DEGRADATION OF ANDROGEN RECEPTOR (AR) BY CONJUGATION OF AR ANTAGONISTS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303538-A1 | GALECTIN-3 INHIBITORS | LGALS3, LGALS1, LGALS3BP | CRBN 3037/4885CASP1 690/4885CASP7 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.